Jared E. Matya, PharmD, BCOP, of Nebraska Medicine, discusses oral agents and their toxicity profiles, as well as newer-generation agents that are often more selective and better tolerated. He describes how toxicity monitoring and management help to ensure patients with cancer remain on treatment.
David S. Kroll, MD, of Brigham and Women’s Hospital, discusses the symptoms of distress in patients with lymphoma and other oncologic malignancies, risk factors for poor outcomes, and how best to approach the management of depression and anxiety in this population.
Alison J. Moskowitz, MD, of Memorial Sloan Kettering Cancer Center, discusses the combination ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), individualized approaches for treating patients with Hodgkin lymphoma, and novel methods for risk stratification.
Stephen M. Ansell, MD, PhD, of the Mayo Clinic, and Bruce D. Cheson, MD, of the Lymphoma Research Foundation, engage in a lively debate about CAR T-cell therapy, how it fits in with immunotherapy and nonchemotherapy approaches, and how to decide which treatment is right for which patient, especially given the many challenges of obtaining CAR T cells.
Peihua Lu, MD, of Lu Daopei Hospital, discusses the state of research in China on CAR T-cell therapy, placing it in the context of the global development pipeline and the progress being made.
